expanding the right to try act to include certain qualifying severe illness and permitting certain regenerative stem cell therapies under the act.

HB 1292 expands New Hampshire's Right to Try Act to allow patients with "qualifying severe illness" access to unapproved treatments. The bill adds new rules for regenerative stem cell therapies, requiring patient consent, facility accreditation, and clear advertising disclosures. It specifically prohibits the use of stem cells derived from fetal or embryonic sources after an abortion. This policy change directly affects New Hampshire residents with severe illnesses who seek experimental treatments not yet approved by the FDA.